Patents by Inventor Marina Bubis
Marina Bubis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180298109Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: January 29, 2018Publication date: October 18, 2018Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
-
Patent number: 10098934Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.Type: GrantFiled: March 18, 2013Date of Patent: October 16, 2018Assignee: COMPUGEN LTDInventors: Zurit Levine, Amir Toporik, Amit Novik, Anat Cohen-Dayag, Avi Rosenberg, Cynthia Koifman, Dalit Landesman-Milo, Eve Montia, Galit Rotman, Liat Dassa, Marina Bubis, Merav Beiman, Ofer Levy, Sergey Nemzer, Shira Walach, Shirley Sameach- Greenwald, Tania Pergam, Yaron Kinar
-
Publication number: 20170037141Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: January 30, 2016Publication date: February 9, 2017Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH- GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
-
Patent number: 9555087Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.Type: GrantFiled: August 26, 2014Date of Patent: January 31, 2017Assignee: COMPUGEN LTDInventors: Amir Toporik, Amit Novik, Anat Cohen-Dayag, Avi Yeshah Rosenberg, Cynthia Koifman, Dalit Landesman-Milo, Eve Montia, Galit Rotman, Liat Dassa, Marina Bubis, Merav Beiman, Ofer Levi, Sergey Nemzer, Tania Pergam, Yaron Kinar, Shirley Sameach- Greenwald, Zurit Levine, Shira Walach
-
Patent number: 9439950Abstract: Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.Type: GrantFiled: September 14, 2015Date of Patent: September 13, 2016Assignee: MacroCure, Ltd.Inventors: Mitchell Shirvan, Eilat Bain, Marina Bubis, Irene Ginis
-
Patent number: 9375466Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.Type: GrantFiled: May 29, 2013Date of Patent: June 28, 2016Assignee: COMPUGEN LTDInventors: Anat Cohen-Dayag, Merav Beiman, Liat Dassa, Marina Bubis, Shirley Sameach- Greenwald, Dalit Landesman-Milo, Cynthia Koifman, Ofer Levy, Sergey Nemzer, Tania Pergam, Yaron Kinar, Zurit Levine, Avi Rosenberg, Galit Rotman, Eve Montia, Amit Novik, Amir Toporik, Shira Walach
-
Publication number: 20160089420Abstract: Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.Type: ApplicationFiled: September 14, 2015Publication date: March 31, 2016Applicant: MACROCURE LTD.Inventors: Mitchell Shirvan, Eilat Bain, Marina Bubis, Irene Ginis
-
Publication number: 20150352151Abstract: Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.Type: ApplicationFiled: June 23, 2015Publication date: December 10, 2015Applicant: MACROCURE LTD.Inventors: Mitchell SHIRVAN, Eilat SHINAR, Orit FRENKEL, Adi ZULOFF-SHANI, Marina BUBIS, Eilat BAIN, Irene GINIS
-
Patent number: 9168287Abstract: Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.Type: GrantFiled: September 8, 2011Date of Patent: October 27, 2015Assignee: MacroCure, Ltd.Inventors: Mitchell Shirvan, Eilat Bain, Marina Bubis, Irene Ginis
-
Patent number: 9132154Abstract: Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.Type: GrantFiled: September 3, 2013Date of Patent: September 15, 2015Assignee: Macrocure Ltd.Inventors: Mitchell Shirvan, Eilat Shinar, Orit Frenkel, Adi Zuloff-Shani, Marina Bubis, Eilat Bain, Irene Gillis
-
Patent number: 9107862Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: GrantFiled: February 15, 2013Date of Patent: August 18, 2015Assignee: Compugen Ltd.Inventors: Amir Toporik, Amit Novik, Anat Cohen-Dayag, Avi Yeshah Rosenberg, Cynthia Koifman, Dalit Landesman-Milo, Eve Montia, Galit Rotman, Liat Dassa, Marina Bubis, Merav Beiman, Ofer Levy, Sergey Nemzer, Tania Pergam, Yaron Kinar, Shirley Sameach-Greenwald, Zurit Levine, Shira Walach
-
Publication number: 20150071892Abstract: Methods of making activated immunostimulatory cell compositions, activated immunostimulatory cell compositions, and methods of using those compositions to stimulate therapeutic immune response to infectious organisms are described.Type: ApplicationFiled: March 13, 2013Publication date: March 12, 2015Inventors: Irene Ginis, Alan Smith, Marina Bubis, Mitchell Shirvan
-
Publication number: 20150030635Abstract: Methods of making activated immunostimulatory cell compositions, activated immunostimulatory cell compositions, and methods of using those compositions to stimulate therapeutic immune responses to tumors are described.Type: ApplicationFiled: March 13, 2013Publication date: January 29, 2015Inventors: Irene Ginis, Alan Smith, Adi Zuloff-Shani, Marina Bubis, Mitchell Shirvan
-
Publication number: 20140363446Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: August 26, 2014Publication date: December 11, 2014Inventors: Amir TOPORIK, Amit NOVIK, Anat COHEN-DAYAG, Avi Yeshah ROSENBERG, Cynthia KOIFMAN, Dalit LANDESMAN-MILO, Eve MONTIA, Galit ROTMAN, Liat DASSA, Marina BUBIS, Merav BEIMAN, Ofer LEVI, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Shirley SAMEACH- GREENWALD, Zurit LEVINE, Shira WALACH
-
Publication number: 20140255411Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants a which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: March 18, 2013Publication date: September 11, 2014Applicant: COMPUGEN LTD.Inventors: Zurit LEVINE, Amir TOPORIK, Amit NOVIK, Anat COHEN-DAYAG, Avi ROSENBERG, Cynthia KOIFMAN, Dalit LANDESMAN-MILO, Eve MONTIA, Galit ROTMAN, Liat DASSA, Marina BUBIS, Merav BEIMAN, Ofer LEVY, Sergey NEMZER, Shira WALACH, Shirley SAMEACH- GREENWALD, Tania PERGAM, Yaron KINAR
-
Publication number: 20140255389Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: May 29, 2013Publication date: September 11, 2014Applicant: COMPUGEN LTD.Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH- GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
-
Publication number: 20140220011Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, ClORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and ClORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: February 15, 2013Publication date: August 7, 2014Applicant: COMPUGEN LTD.Inventors: Amir TOPORIK, Amit NOVIK, Anat COHEN-DAYAG, Avi Yeshah ROSENBERG, Cynthia KOIFMAN, Dalit LANDESMAN-MILO, Eve MONTIA, Galit ROTMAN, Liat DASSA, Marina BUBIS, Merav BEIMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Shirley SAMEACH-GREENWALD, Zurit LEVINE, Shira WALACH
-
Publication number: 20140004091Abstract: Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.Type: ApplicationFiled: September 3, 2013Publication date: January 2, 2014Applicant: Macrocure Ltd.Inventors: Mitchell Shirvan, Eilat Shinar, Orit Frenkel, Adi Zuloff-Shani, Marina Bubis, Eilat Bain, Irene Gillis
-
Patent number: 8574902Abstract: Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds.Type: GrantFiled: September 2, 2011Date of Patent: November 5, 2013Assignee: Macrocure Ltd.Inventors: Mitchell Shirvan, Eilat Shinar, Orit Frenkel, Adi Zuloff-Shani, Marina Bubis, Eilat Bain, Irene Ginis
-
Publication number: 20130224148Abstract: Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.Type: ApplicationFiled: September 8, 2011Publication date: August 29, 2013Inventors: Mitchell Shirvan, Eilat Bain, Marina Bubis, Irene Ginis